Vericiguat specifically enhances sGC activity, thus targeting the NO-sGC-cGMP pathway, whereas other pharmacological agents for HF, such as sacubitril/valsartan, primarily act on the NP-pGC-cGMP pathway [17]. Here, SGCB is linked to hydrops fetalis.